Transcode Therapeutics RNAZ Income Statement (2020-2026)

NASDAQ RNAZ
$2.97 -0.24 (-7.48%)
At close: Aug 20, 2026 · 4:00 PM EDT
Income Statement Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026
Shares Outstanding (Entity) (Quarter)
6.0017.0011.0018.0018.0018.0018.0021.0036.0085.00194.000.01M0.01M0.02M0.01M0.17M0.83M0.83M0.69M0.92M
Operating items
Research & Development (Quarter)
0.21M0.99M1.29M1.88M2.62M3.04M2.69M2.59M2.97M3.34M3.36M1.76M3.08M1.23M3.64M2.22M2.57M3.16M5.48M5.11M
Selling, General & Administrative (Quarter)
0.14M1.37M1.70M1.60M2.09M1.91M2.81M2.30M2.16M1.97M0.73M1.53M2.03M0.94M1.45M0.95M1.66M1.40M1.76M2.22M
Other Operating Expenses (Quarter)
8.79M10.43M
Operating Expenses (Quarter)
0.36M2.36M2.99M3.48M4.71M4.95M5.50M4.89M5.12M5.31M4.10M3.29M5.11M2.17M5.09M3.17M4.22M4.56M16.03M17.76M
Operating Income (Quarter)
-0.36M-2.36M-2.99M-3.48M-4.71M-4.95M-5.50M-4.89M-5.12M-5.31M-4.10M-3.29M-5.11M-2.17M-5.09M-3.17M-4.22M-4.56M-16.03M-17.76M
EBIT (Quarter)
-0.36M-2.36M-2.99M-3.48M-4.71M-4.95M-5.50M-4.89M-5.12M-5.31M-4.10M-3.29M-5.11M-2.17M-5.09M-3.17M-4.22M-4.56M-16.03M-17.76M
Non-operating items
Interest & Investment Income (Quarter)
1.00141.00510.00442.000.00M0.01M0.01M0.00M246.00131.00137.00168.00178.00179.00159.00146.00148.00147.000.08M0.09M
Other Non Operating Income (Quarter)
3.07M-0.06M-0.07M-0.16M0.23M-0.03M-0.05M-0.03M-0.01M-0.02M
Non Operating Income (Quarter)
3.13M0.03M0.19M0.01M0.04M0.66M0.36M0.07M0.78M0.01M0.01M-0.04M-0.08M-0.16M-0.82M-8.91M-0.06M-0.29M2.81M0.20M
Net income details
EBT (Quarter)
2.77M-7.15M-2.91M-3.52M-5.75M-5.64M-5.50M-5.01M-5.31M-5.48M-4.11M-3.40M-5.15M-2.28M-5.08M-12.09M-4.23M-4.63M-15.99M-17.55M
Profit After Tax (Quarter)
2.77M-2.33M-2.80M-3.47M-4.67M-4.29M-5.13M-4.82M-4.34M-5.30M-4.09M-3.33M-5.19M-2.32M-5.95M-12.09M-4.28M-4.86M-15.05M-19.51M
Income from Continuing Operations (Quarter)
2.77M-7.15M-2.91M-3.52M-5.75M-5.64M-5.50M-5.01M-5.31M-5.48M-4.11M-3.40M-5.15M-2.28M-5.08M-12.09M-4.23M-4.63M-15.99M-17.55M
Consolidated Net Income (Quarter)
2.77M-7.15M-2.91M-3.52M-5.75M-5.64M-5.50M-5.01M-5.31M-5.48M-4.11M-3.40M-5.15M-2.28M-5.08M-12.09M-4.23M-4.63M-15.99M-17.55M
Income towards Parent Company (Quarter)
2.77M-7.15M-2.91M-3.52M-5.75M-5.64M-5.50M-5.01M-5.31M-5.48M-4.11M-3.40M-5.15M-2.28M-5.08M-12.09M-4.23M-4.63M-15.99M-17.55M
Preferred Dividend Payments (Quarter)
1.73M
Net Income towards Common Stockholders (Quarter)
2.77M-7.15M-2.91M-3.52M-5.75M-5.64M-5.50M-5.01M-5.31M-5.48M-4.11M-3.33M-5.19M-2.32M-5.95M-12.09M-4.28M-4.86M-15.05M-19.51M
Additional items
EPS (Basic) (Quarter)
0.46M-0.45M-0.26M-0.20M-0.32M-0.31M-0.31M-0.26M-0.15M-0.06M-0.02M-597.92-680.41-146.10-467.61-70.17-5.13-5.82-21.83-21.28
EPS (Diluted) (Quarter)
0.40M-0.45M-0.26M-0.20M-0.32M-0.31M-0.31M-0.26M-0.15M-0.06M-0.02M-597.92-680.41-146.10-467.61-70.17-5.13-5.82-21.83-21.28
Shares Outstanding (Quarter)
6.0016.0011.0018.0018.0018.0018.0019.0036.0085.00194.000.01M0.01M0.02M0.01M0.17M0.83M0.83M0.69M0.92M
Shares Outstanding (Diluted) (Quarter)
7.0016.0011.0018.0018.0018.0018.0019.0036.0085.00194.000.01M0.01M0.02M0.01M0.17M0.83M0.83M0.69M0.92M
EBITDA (Quarter)
-0.36M-2.36M-2.99M-3.48M-4.71M-4.95M-5.50M-4.89M-5.12M-5.31M-4.10M-3.29M-5.11M-2.17M-5.09M-3.17M-4.22M-4.56M-16.03M-17.76M
Interest Expenses (Quarter)
6.43M4.79M-0.08M0.04M1.04M0.70M0.02M0.13M0.19M0.17M0.01M0.11M0.04M0.11M-0.01M0.06M0.01M0.07M0.04M